Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development

Nearly 100% protection against malaria infection can be achieved in humans by immunization with P. falciparum radiation-attenuated sporozoites (RAS). Although it is thought that protection is mediated by T cell and antibody responses, only a few of the many pre-erythrocytic (sporozoite and liver sta...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 10; no. 8; p. e0136109
Main Authors Aguiar, Joao C., Bolton, Jessica, Wanga, Joyce, Sacci, John B., Iriko, Hideyuki, Mazeika, Julie K., Han, Eun-Taek, Limbach, Keith, Patterson, Noelle B., Sedegah, Martha, Cruz, Ann-Marie, Tsuboi, Takafumi, Hoffman, Stephen L., Carucci, Daniel, Hollingdale, Michael R., Villasante, Eileen D., Richie, Thomas L.
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 20.08.2015
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Nearly 100% protection against malaria infection can be achieved in humans by immunization with P. falciparum radiation-attenuated sporozoites (RAS). Although it is thought that protection is mediated by T cell and antibody responses, only a few of the many pre-erythrocytic (sporozoite and liver stage) antigens that are targeted by these responses have been identified. Twenty seven P. falciparum pre-erythrocytic antigens were selected using bioinformatics analysis and expression databases and were expressed in a wheat germ cell-free protein expression system. Recombinant proteins were recognized by plasma from RAS-immunized subjects, and 21 induced detectable antibody responses in mice and rabbit and sera from these immunized animals were used to characterize these antigens. All 21 proteins localized to the sporozoite: five localized to the surface, seven localized to the micronemes, cytoplasm, endoplasmic reticulum or nucleus, two localized to the surface and cytoplasm, and seven remain undetermined. PBMC from RAS-immunized volunteers elicited positive ex vivo or cultured ELISpot responses against peptides from 20 of the 21 antigens. These T cell and antibody responses support our approach of using reagents from RAS-immunized subjects to screen potential vaccine antigens, and have led to the identification of a panel of novel P. falciparum antigens. These results provide evidence to further evaluate these antigens as vaccine candidates. ClinicalTrials.gov NCT00870987 ClinicalTrials.gov NCT00392015.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
Conceived and designed the experiments: JCA. Performed the experiments: JCA JB JW JBS HI JKM E-TH. Analyzed the data: JCA JB JBS TT MRH. Contributed reagents/materials/analysis tools: JBS NBP TT MS. Wrote the paper: JCA NBP A-MC SLH MRH EDV TLR. Provided technical and scientific advice: KL SLH DC TLR. Established assays: MS.
Competing Interests: JCA is an employee of Camris International. JW is an employee of Technical Resources International, Inc. JKM is an employee of EMD Millipore Corporation. There are no patents, products in development, or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Current address: Sanaria, 9800 Medical Center Drive, Suite A209, Rockville, MD 20850, United States of America
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0136109